• Richard Ulevitch has been named a venture partner at 5AM Ventures (Menlo Park, California). Ulevitch joins 5AM Ventures from the Scripps Research Institute. The company also reported the promotion of two of the firm’s senior associates, Kevin Forrest, PhD, and Andrew McMillan, PhD, to principal. Forrest and McMillan have been with the 5AM team since early 2005. 5M Ventures says it specializes in seed and early-stage investments in “next-generation” life science companies.

• AngioDynamics (Queensbury, New York) said that Robert Mitchell, the company’s COO, has resigned his position, effective Feb. 29, to become the CEO of Nellix Endovascular, a start-up medical device company. AngioDynamics makes devices used by interventional radiologists, nephrologists for the minimally invasive treatment of cancer and peripheral vascular disease.

• Matt Meyer has been named VP of marketing of KFx Medical (San Diego). Previously, Meyer was group director of Medtronic’s spinal and biologics business in Memphis, Tennessee. KFx makes solutions for rotator cuff repair.

• Joel Naor, MD, has been named chief medical officer of MacuSight (Union City, California). Naor formerly was senior medical director at Allergan. MacuSight makes therapeutics for treating ocular diseases and conditions.

• New England Research Institutes (NERI; Watertown, Massachusetts) reported promoting Rebecca Li, PhD, from principal research scientist and clinical director to VP of clinical research. NERI is a contract research organization.

• Pamela Harris has been named VP for diabetes sales, managed care and government accounts at Novo-Nordisk (Princeton, New Jersey). She joined the company in 2005 from Novartis. Novo Nordisk specializes in diabetes care.

• Helge Bastian, PhD, has been named VP of global marketing for the research biotech business unit of Sigma-Aldrich (St. Louis). Bastain was previously executive VP of the life science services business at SGS. Sigma-Aldrich is a life science company.